Therefore, these results may indicate that KRAS-mutant CRC harbor a more immunosuppressive microenvironment, which significantly limits the use of immune checkpoint inhibitors as monotherapy in this group of CRC patients. Here, KRAS is linked to colorectal carcinoma.